Possible correlation between basal donor/recipient allelic discrepancies and post-transplant outcome (GvHD) development, neutrophil engraftment, relapse, DFS and OS.

26 patient received myeloablative conditioning regimen and 85 received reduced conditioning regimen.

GvHD prophylaxis with CSA and MTX in 61 pts, CSA and mycophenolate mofetil in 43 pts and CSA in 7 pts.

65 patients received graft from sibling donor and 46 patients from unrelated donor.

Allelic status performed using multiplex PCR amplification of ten STR loci.

Patients with mismatch (D8S1179)locus have neutrophil engraftment at 18 days (CI 95% 17.202-18.798) compared with 21 days (CI 95% 17.328-24.672) of match patients (p=0.007).

Patients with mismatch (D3S1358)locus developed aGvHD at 20 days (CI 95% 15.781-24.219) compared with 29 days (CI 95% 15.421-42.579) of match ones (p=0.031).

Patients with mismatch (D3S1358)locus have an OS of 16 months (CI 95% 11.016-20.984) compared with 41 months (CI 95% 25.420-56.580) of match ones (p=0.025).

Patients with mismatch (D8S1179)locus have an OS of 16 months (CI 95% 8.528-23.472) compared with 56 months (CI 95% 11.254-78.057) of match ones (p=0.012).